Cormorant Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Cormorant Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.59M	Sell	175,000 -275,000	-61%	-$6.41M	0.24%	40
2026 Q1	$10.6M	Sell	450,000 -50,000	-10%	-$1.28M	0.53%	34
2025 Q4	$14.5M	Sell	500,000 -275,000	-35%	-$7.04M	0.67%	27
2025 Q3	$14.6M	Sell	775,000 -225,000	-23%	-$3.55M	1.01%	24
2025 Q2	$14M	Sell	1,000,000 -350,000	-26%	-$4.91M	1.04%	22
2025 Q1	$21.1M	Sell	1,350,000 -475,000	-26%	-$6.69M	1.59%	18
2024 Q4	$25.4M	Sell	1,825,000 -500,000	-22%	-$5.48M	1.4%	22
2024 Q3	$21.6M	Sell	2,325,000 -200,000	-8%	-$1.97M	1.15%	27
2024 Q2	$23.5M	Buy	2,525,000 +400,000	+19%	+$3.62M	1.36%	24
2024 Q1	$21.1M	Buy	+2,125,000	New	+$15.9M	0.92%	32
2023 Q3	–	Sell	-800,000	Closed	-$7.62M	–	52
2023 Q2	$7.62M	Buy	+800,000	New	+$8.88M	0.43%	44
2023 Q1	–	Sell	-650,000	Closed	-$9.62M	–	77
2022 Q4	$9.62M	Sell	650,000 -350,000	-35%	-$6.11M	0.64%	40
2022 Q3	$19.1M	Buy	+1,000,000	New	+$22.7M	1.34%	28

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cormorant Asset Management's ARQT Position: Q2 2026 in Review

Cormorant Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 61% in Q2 2026, selling an estimated $6.41M and leaving 175,000 shares worth $4.59M. The position accounts for 0.24% of the portfolio, ranked #40.

Cormorant Asset Management first reported a position in ARQT in Q3 2022 and has held it in 13 quarters since. The position peaked at $25.4M in Q4 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Cormorant Asset Management held 175,000 shares of Arcutis Biotherapeutics worth $4.59M as of Q2 2026.
Cormorant Asset Management sold 275,000 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.41M.
Arcutis Biotherapeutics made up 0.24% of Cormorant Asset Management's portfolio in Q2 2026, its #40 holding.
Cormorant Asset Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 13 quarters since.
Cormorant Asset Management's Arcutis Biotherapeutics position peaked at $25.4M in Q4 2024.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.